behavior/neurological
|
• at 3-5 months of age, tamoxifen-treated male mice show impaired performance in the Morris water maze assay, akin to that observed in mice homozygous for the Trim47em1(IMPC)Bay allele
|
|
• at 3-5 months of age, tamoxifen-treated male mice show impaired performance in the Y-maze assay, akin to that observed in mice homozygous for the Trim47em1(IMPC)Bay allele
|
nervous system
|
• tamoxifen-treated adult mice show impaired blood-brain barrier (BBB) function, as indicated by an increased BBB permeability index following 3 kDa dextran injection and reduced expression of key adherens and tight junction components in brain endothelial cells (ECs)
|
cellular
|
• qPCR analysis indicated downregulation of critical Nrf2 target genes, including Hmox1 and Slc7a11, in brain ECs
|
cardiovascular system
|
• tamoxifen-treated adult mice show impaired blood-brain barrier (BBB) function, as indicated by an increased BBB permeability index following 3 kDa dextran injection and reduced expression of key adherens and tight junction components in brain endothelial cells (ECs)
|
growth/size/body
| N |
• at 3-5 months of age, tamoxifen-treated male mice show no significant differences in body weight relative to control littermates
|
renal/urinary system
| N |
• tamoxifen-treated adult mice show normal glomerular filtration barrier function in the kidney
|


Analysis Tools